FIELD: medicine; pharmacology.
SUBSTANCE: invention relates to the amyloid-binding compound or its water-soluble non-toxic salt, where Y is presented by NR1R2; Z means S; R1 is chosen from group consisting of H, methyl, propyl, (CH2)nOR' (where n = 1, 2 or 3 and R' is presented by H or by lowest alkyl group), CF3, CH2-CH2X, CH2-CH2-CH2X (where X = F, Cl, Br or I); where R2 is chosen from group consisting of lowest alkyl group, (CH2)nOR' (where n = 1, 2 or 3 and R' is presented by H or by lowest alkyl group), CF3, CH2-CH2X, CH2-CH2-CH2X (where X = F, Cl, Br or I); R3 - R10 are chosen independently from group, consisting of H, F, CI, Br, I, lowest alkyl group, (CH2)nOR' (where n = 1, 2 or 3) or OR' , and R' means H lowest alkyl group); provided, the compound isn't related one of the following compounds: methyl-[4-(6- methyl -benzothiazole-2-il)phenyl]amin, dimethyl -[4-(6- methyl - benzothiazole-2-il)phenyl]amin, and where at least one of R1-R10 substitutors contains the radioactive marker, chosen from group, which consists of 11C, 123I, 125I or 127I, and the described compounds don't contain the nitrogen quaternary atoms. The invented compounds are used for detection of the amyloid deposit in patient and in differential diagnostics of brain affected by Alzhemer's disease and normal brain. 
.
EFFECT: thioflavin derivatives are obtained for in vivo visualization and identification of amyloid deposit in patient.
16 cl, 2 tbl, 9 dwg, 9 ex
